0A4Y Stock Overview
An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
AIM ImmunoTech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.21 |
52 Week High | US$0.60 |
52 Week Low | US$0.18 |
Beta | -0.36 |
11 Month Change | -15.64% |
3 Month Change | -42.24% |
1 Year Change | -55.37% |
33 Year Change | -85.47% |
5 Year Change | n/a |
Change since IPO | -99.15% |
Recent News & Updates
Recent updates
Shareholder Returns
0A4Y | GB Biotechs | GB Market | |
---|---|---|---|
7D | -9.1% | 0.3% | 2.2% |
1Y | -55.4% | -18.3% | 8.0% |
Return vs Industry: 0A4Y underperformed the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0A4Y underperformed the UK Market which returned 8% over the past year.
Price Volatility
0A4Y volatility | |
---|---|
0A4Y Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 10.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 0A4Y's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1966 | 27 | Thomas Equels | aimimmuno.com |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
0A4Y fundamental statistics | |
---|---|
Market cap | US$13.38m |
Earnings (TTM) | -US$23.93m |
Revenue (TTM) | US$190.00k |
70.4x
P/S Ratio-0.6x
P/E RatioIs 0A4Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0A4Y income statement (TTM) | |
---|---|
Revenue | US$190.00k |
Cost of Revenue | US$36.00k |
Gross Profit | US$154.00k |
Other Expenses | US$24.08m |
Earnings | -US$23.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.38 |
Gross Margin | 81.05% |
Net Profit Margin | -12,594.21% |
Debt/Equity Ratio | 93.8% |
How did 0A4Y perform over the long term?
See historical performance and comparison